Protocol summary

Study aim
To compare the efficacy and safety of oral tranexamic acid with intradermal tranexamic acid mesotherapy in women with melasma.
Design
A parallel-group randomized clinical trial with 1:1 allocation using a random number table.
Settings and conduct
Eligible participants will be evaluated at baseline and followed during treatment and the post-treatment follow-up period. Clinical assessment will be performed using the modified Melasma Area and Severity Index (mMASI), MELASQoL, and standardized facial imaging with VisioFace and DermLite 4
Participants/Inclusion and exclusion criteria
Women aged 18–45 years with clinically diagnosed melasma and Fitzpatrick skin phototypes I–IV will be enrolled. Exclusion criteria include a history of venous or arterial thrombosis, thromboembolic disorders or predisposition to thrombosis, significant coagulation disorders, concomitant medications affecting coagulation that may make participation inappropriate, pregnancy or breastfeeding, known hypersensitivity to tranexamic acid, severe renal disease or significant renal impairment, history of seizures, severe systemic conditions that may interfere with study participation or safety assessment, active skin disease at the injection site, and recent treatments for melasma that may interfere with treatment response.
Intervention groups
Participants two treatment groups. oral tranexamic acid group will receive tranexamic acid 250 mg twice daily for 12 weeks. The intradermal tranexamic acid mesotherapy group will receive intradermal tranexamic acid injections every 2 weeks for 12 weeks.participants will receive sunscreen SPF 50 and standardized sun-avoidance advice.
Main outcome variables
change in mMASI score from baseline to 12 weeks after treatment initiation. visual analogue scale (VAS), recurrence of melasma during the 3-month post-treatment follow-up period, and treatment-related adverse events.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20220117053743N4
Registration date: 2026-11-16, 1405/08/25
Registration timing: prospective

Last update: 2026-11-16, 1405/08/25
Update count: 0
Registration date
2026-11-16, 1405/08/25
Registrant information
Name
Aida Farmani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 31 3261 6408
Email address
aida.farmani.med@gmail.com
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-11-20, 1405/08/29
Expected recruitment end date
2027-05-19, 1406/02/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the Efficacy and Safety of Oral Versus Intradermal Tranexamic Acid in the Treatment of Melasma: A Randomized Clinical Trial
Public title
Comparison of the Efficacy and Safety of Oral Versus Intradermal Tranexamic Acid in the Treatment of Melasma: A Randomized Clinical Trial
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Women aged 18–45 years.Clinical diagnosis of facial melasma.Presence of melasma on the face.Willingness to participate and signing written informed consent.No recent 3 months use of systemic or topical treatments that may significantly affect melasma.
Exclusion criteria:
A history of venous or arterial thrombosis.Thromboembolic disorders or a known predisposition to thrombosis.Significant coagulation disorders.Concomitant use of medications affecting coagulation that may make participation in the study inappropriate.Pregnancy or breastfeeding.Known hypersensitivity to tranexamic acid.Severe renal disease or significant renal impairment.A history of seizures.Severe systemic diseases or medical conditions that, in the investigator’s judgment, may interfere with study participation or affect the safety or assessment of the treatment.Active skin disease at the injection site.Recent use of treatments for melasma that may interfere with the assessment of treatment response.
Age
From 18 years old to 45 years old
Gender
Female
Phase
3
Groups that have been masked
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 20
Randomization (investigator's opinion)
Randomized
Randomization description
Participants will be randomly allocated to the two study groups in a 1:1 ratio using a random number table.
Blinding (investigator's opinion)
Single blinded
Blinding description
The study will use single-blind methodology, in which the data analyst will be blinded to the treatment allocation throughout the statistical analysis.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
دانشکده پزشکی - دانشگاه علوم پزشکی اصفهان (کمیته اخلاق در پژوهش)
Street address
Isfahan . medical University
City
Isfahan
Province
Isfehan
Postal code
8158799346
Approval date
2026-07-22, 1405/04/31
Ethics committee reference number
IR.MUI.MED.REC.1405.171

Health conditions studied

1

Description of health condition studied
Chloasma
ICD-10 code
L81.1
ICD-10 code description
Chloasma

Primary outcomes

1

Description
Change in the modified Melasma Area and Severity Index (mMASI) score, reflecting the severity of melasma based on the extent and intensity of pigmentation in the affected facial areas.
Timepoint
At baseline (before initiation of treatment) and at 12 weeks after treatment initiation.
Method of measurement
The mMASI score will be assessed clinically by a dermatologist using standardized evaluation of the extent and intensity of facial hyperpigmentation in the four facial regions (forehead, right malar, left malar, and chin). The score will be calculated according to the standard mMASI scoring system.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: oral Tranexamic acid 250 mg BID
Category
Treatment - Drugs

2

Description
Control group: Intradermal Tranexamic acid 100mg/cc
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
کلینیک های درماتولوژی وابسته به دانشگاه علوم پزشکی اصفهان به انگلیسی
Full name of responsible person
Aida Farmani
Street address
Hezar Jarib street
City
Isfahan
Province
Isfehan
Postal code
8158799346
Phone
+98 31 3261 6408
Email
aida.farmani.med@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Aida Farmani
Street address
Isfahan University of Medical Sciences
City
Esfahan
Province
Isfehan
Postal code
8158799346
Phone
+98 913 409 0453
Email
Aida.farmani.med@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
aida Farmani
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Isfahan
City
Isfahan
Province
Isfehan
Postal code
8158799346
Phone
+98 31 3261 6408
Email
aida.farmani.med@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Aida Farmani
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Hezarjarib
City
Isfahan
Province
Isfehan
Postal code
8158799346
Phone
+98 31 3261 6408
Email
aida.farmani.med@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Aida Farmani
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
AL-Zahra hospital
City
isfahan
Province
Isfehan
Postal code
8158799346
Phone
+98 913 409 0453
Email
Aida.farmani.med@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
Due to ethical considerations, participant privacy, and the need to ensure appropriate data protection, individual participant data will not be made publicly available. De-identified data may be considered for sharing upon reasonable request, subject to approval by the principal investigator and compliance with institutional and ethical requirements.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...